(Q26780412)

English

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group

scientific article

In more languages

Statements

scholarly article

0 references

7 references

23 March 2019

25 April 2019

27 September 2019

27 November 2019

13 December 2019

26 October 2020

27 May 2022

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group (English)

0 references

progressive multifocal leukoencephalopathy

6 references

23 March 2019

25 April 2019

27 September 2019

27 November 2019

13 December 2019

26 October 2020

monoclonal antibody

1 reference

27 September 2019

1 reference

27 November 2019

1 reference

13 December 2019

immunosuppressive drug

1 reference

26 October 2020

author name string

C McGuigan

1

0 references

M Craner

2

0 references

J Guadagno

3

0 references

R Kapoor

4

0 references

G Mazibrada

5

0 references

P Molyneux

6

0 references

R Nicholas

7

0 references

J Palace

8

0 references

O R Pearson

9

0 references

D Rog

10

0 references

C A Young

11

0 references

language of work or name

0 references

publication date

February 2016

0 references

1 February 2016

7 references

23 March 2019

25 April 2019

27 September 2019

27 November 2019

13 December 2019

26 October 2020

27 May 2022

Journal of Neurology, Neurosurgery and Psychiatry

7 references

23 March 2019

25 April 2019

27 September 2019

27 November 2019

13 December 2019

26 October 2020

27 May 2022

87

0 references

117-25

0 references

2

0 references

copyright license

Creative Commons Attribution-NonCommercial

7 references

23 March 2019

25 April 2019

27 September 2019

27 November 2019

13 December 2019

26 October 2020

27 May 2022

on focus list of Wikimedia project

0 references

Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

7 April 2017

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

7 April 2017

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

7 April 2017

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

7 April 2017

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

7 April 2017

Anti-JC virus antibody titres increase over time with natalizumab treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

JC virus antibody status underestimates infection rates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

Changes to anti-JCV antibody levels in a Swedish national MS cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

Immune reconstitution inflammatory syndrome in natalizumab-associated PML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

28 September 2017

Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

31 May 2018

MRI pattern in asymptomatic natalizumab-associated PML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

31 May 2018

Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

31 May 2018

Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

31 May 2018

Progressive multifocal leukoencephalopathy after natalizumab discontinuation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

31 May 2018

JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

31 May 2018

JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

31 May 2018

Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

31 May 2018

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4752634

31 May 2018

Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab.

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2015-311100

21 January 2018

The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas?

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2015-311100

21 January 2018

MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2015-311100

21 January 2018

Anti-JC virus antibodies: implications for PML risk stratification

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2015-311100

21 January 2018

Progressive multifocal leukoencephalopathy after natalizumab monotherapy.

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2015-311100

21 January 2018

Isolated motor control dysfunction related to progressive multifocal leukoencephalopathy during AIDS with normal MRI.

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2015-311100

21 January 2018

Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy.

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2015-311100

21 January 2018

Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2015-311100

21 January 2018

Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance

1 reference

https://pubmed.ncbi.nlm.nih.gov/26492930

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS

1 reference

https://pubmed.ncbi.nlm.nih.gov/26492930

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Value of MRI as a surrogate marker for PML in natalizumab long-term therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26492930

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/JNNP-2015-311100

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26780412&oldid=1957593130"